Advanced

Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine

Urey, Carlos LU ; Andersson, Bodil LU ; Ansari, Daniel LU ; Sasor, Agata; Said-Hilmersson, Katarzyna LU ; Nilsson, Johan LU and Andersson, Roland LU (2017) In Scandinavian Journal of Gastroenterology 52(5). p.595-600
Abstract

Background: Previous in vitro studies have shown that mucin 4 (MUC4) confers resistance toward gemcitabine in pancreatic cancer cells. To date, there are few clinical studies corroborating these findings. The aim of this study was to evaluate the predictive impact of MUC4 expression on survival in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. Materials and methods: MUC4 expression was investigated by immunohistochemistry in 78 tissue sections from patients with pancreatic ductal adenocarcinoma undergoing Whipple resection. The H-score was used to evaluate MUC4 expression. The Kaplan–Meier method and Cox proportional hazards regression analysis were used to assess the predictive role of MUC4 expression.... (More)

Background: Previous in vitro studies have shown that mucin 4 (MUC4) confers resistance toward gemcitabine in pancreatic cancer cells. To date, there are few clinical studies corroborating these findings. The aim of this study was to evaluate the predictive impact of MUC4 expression on survival in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. Materials and methods: MUC4 expression was investigated by immunohistochemistry in 78 tissue sections from patients with pancreatic ductal adenocarcinoma undergoing Whipple resection. The H-score was used to evaluate MUC4 expression. The Kaplan–Meier method and Cox proportional hazards regression analysis were used to assess the predictive role of MUC4 expression. Results: The MUC4 protein was expressed in 93.6% (73/78) of pancreatic cancer tissue specimens. None of the normal control pancreatic tissues had any MUC4 expression. Low MUC4 expression (H-score ≤100) was detectable in 42 (53.8%) of tumors and high MUC4 expression (H-score >100) was detectable in 36 (46.2%) of tumors. Low expression of MUC4 was associated with favorable survival (p = .027), whereas high MUC4 expression did not correlate with survival (p = .87) in patients receiving adjuvant gemcitabine treatment. Conclusions: This is the first study indicating a predictive role of MUC4 expression for gemcitabine treatment in the clinical setting.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
gemcitabine, immunohistochemistry, MUC4, mucins, Pancreatic ductal adenocarcinoma
in
Scandinavian Journal of Gastroenterology
volume
52
issue
5
pages
595 - 600
publisher
Taylor & Francis
external identifiers
  • scopus:85012937729
  • wos:000395746800016
ISSN
0036-5521
DOI
10.1080/00365521.2017.1290134
language
English
LU publication?
yes
id
ad20e91a-9656-445f-8d31-adc662b1dd81
date added to LUP
2017-02-27 13:28:39
date last changed
2018-04-29 04:36:39
@article{ad20e91a-9656-445f-8d31-adc662b1dd81,
  abstract     = {<p>Background: Previous in vitro studies have shown that mucin 4 (MUC4) confers resistance toward gemcitabine in pancreatic cancer cells. To date, there are few clinical studies corroborating these findings. The aim of this study was to evaluate the predictive impact of MUC4 expression on survival in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. Materials and methods: MUC4 expression was investigated by immunohistochemistry in 78 tissue sections from patients with pancreatic ductal adenocarcinoma undergoing Whipple resection. The H-score was used to evaluate MUC4 expression. The Kaplan–Meier method and Cox proportional hazards regression analysis were used to assess the predictive role of MUC4 expression. Results: The MUC4 protein was expressed in 93.6% (73/78) of pancreatic cancer tissue specimens. None of the normal control pancreatic tissues had any MUC4 expression. Low MUC4 expression (H-score ≤100) was detectable in 42 (53.8%) of tumors and high MUC4 expression (H-score &gt;100) was detectable in 36 (46.2%) of tumors. Low expression of MUC4 was associated with favorable survival (p = .027), whereas high MUC4 expression did not correlate with survival (p = .87) in patients receiving adjuvant gemcitabine treatment. Conclusions: This is the first study indicating a predictive role of MUC4 expression for gemcitabine treatment in the clinical setting.</p>},
  author       = {Urey, Carlos and Andersson, Bodil and Ansari, Daniel and Sasor, Agata and Said-Hilmersson, Katarzyna and Nilsson, Johan and Andersson, Roland},
  issn         = {0036-5521},
  keyword      = {gemcitabine,immunohistochemistry,MUC4,mucins,Pancreatic ductal adenocarcinoma},
  language     = {eng},
  month        = {02},
  number       = {5},
  pages        = {595--600},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Gastroenterology},
  title        = {Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine},
  url          = {http://dx.doi.org/10.1080/00365521.2017.1290134},
  volume       = {52},
  year         = {2017},
}